HLB Therapeutics said its U.S. subsidiary Regentree failed to achieve statistical significance for the primary endpoint in the topline results of the U.S. Phase 3 clinical trial (SEER-2) of RGN-259, a treatment for neurotrophic keratitis (NK).


HLB Therapeutics' Neurotrophic Keratitis Treatment Fails to Achieve Statistical Significance for Primary Endpoint View original image

According to data HLB Therapeutics received from the contract research organization (CRO) on November 16, there was no statistically significant difference in the healing rate four weeks after treatment, the primary endpoint, between the RGN-259 treatment group and the placebo group.


The company plans to officially receive the full clinical trial data from the CRO within the next few weeks. It will then comprehensively review detailed results for the primary endpoint, as well as secondary endpoints and treatment responses by subgroup, and conduct an in-depth analysis of the clinical results.



"Although the topline results did not show statistical significance for the primary endpoint, we plan to thoroughly analyze the full clinical data and comprehensively assess the detailed results related to treatment efficacy," said HLB Therapeutics CEO Ahn Kihong. "Based on the analysis, we will carefully review our future development direction and plans, and promptly and responsibly take any necessary follow-up measures."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing